Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
These CellCarrier Ultra microplates for high content imaging applications are tissue culture treated and are available in black in a 96-well format. The CellCarrier Ultra HCS microplates benefit from a film bottom made of cyclic olefin, a plastic that has glass-like optical properties, providing superior image quality and also good cell adherence. They have an ultra-low plate bottom (0.2mm) for better well access when using water immersion and high NA objectives, and a new design, low profile polystyrene lid for reduced evaporation. Case of 50.
Drawing on many years of experience in High-Content Screening, PerkinElmer’s expert team has developed and validated the CellCarrier™ Ultra line of microplates. These microplates have been engineered to deliver both perfomance and superior images for high-content applications.
CellCarrier Ultra plates are part of a range of microplates for high content applications, and belong to our complete solution for high content imaging that includes the Operetta® High Content Imaging and Opera Phenix™ High Content Screening Systems, software, and automation.
Well format: 96-well
|Number of Rows||8|
|Number of Columns||12|
|Well volume||425 µL|
|Recommended working volume||Up to 300 µL|
|Well diameter Top (mm)||6.84|
|Well diameter Bottom (mm)||6.4|
|Well depth (mm)||13.95|
|A1 to top offset (mm)||11.24|
|A1 to side offset (mm)||14.38|
|Well-to-well spacing (mm)||9|
|Coating Treatment||TC-treated, Sterile|
|Detection Method||Confocal Imaging, Fluorescence, High Content Imaging|
|Material||Cyclic Olefin, Polystyrene|
|Product Brand Name||CellCarrier|
|Unit Size||Case of 50|
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes COVID-19, the respiratory illness responsible for the COVID-19 pandemic. Studies have shown that patients infected with SARS-CoV-2 with cardiovascular comorbidities are more susceptible to severe infection and thus the case fatality rate in these patients rises. To further understand the pathology of SARS-CoV-2 in cardiomyocytes, a team of researchers from the University of Cambridge in the UK, have developed a screening platform using human embryonic stem cell-derived cardiomyocytes (hESC-CMs).
96-well CellCarrier Ultra microplates: Better microplates means better imaging results